OPL 0301
Alternative Names: OPL-0301Latest Information Update: 03 Mar 2023
At a glance
- Originator Valo Health
- Class Cardiovascular therapies; Ischaemic heart disorder therapies; Urologics
- Mechanism of Action Sphingosine 1 phosphate receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Postmyocardial infarction
- Phase I Acute kidney injury
Most Recent Events
- 16 Feb 2023 Valo Health withdraws a phase II RESTORE trial prior to enrolment in Postmyocardial infarction in USA (PO) based on a business decision (NCT05327855)
- 01 Jun 2022 Phase-II clinical trials in Postmyocardial infarction in USA (PO, Capsule) (NCT05327855)
- 14 Apr 2022 Valo Health plans a phase II RESTORE trial for Postmyocardial infarction in USA (PO, Capsule) (NCT05327855)